N-Descyclopropanecarbaldehyde Olaparib

N-Descyclopropanecarbaldehyde Olaparib is an analogue of Olaparib (HY-10162) containing DOTA moiety. N-Descyclopropanecarbaldehyde Olaparib is a PARP inhibitor used for synthesizing novel dual EGFR and PARP PROTAC, DP-C-4 (HY-141481) [1]. N-Descyclopropanecarbaldehyde Olaparib can be radiolabeled with F-18 or fluorophore for positron emission tomography (PET) or optical imaging in several types of tumor[2].

Product Specifications

CAS Number

[763111-47-3]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Ligands for Target Protein for PROTAC; PARP

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Epigenetics; PROTAC

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/n-descyclopropanecarbaldehyde-olaparib.html

Concentration

10mM

Purity

99.46

Solubility

DMSO : ≥ 100 mg/mL|H2O : < 0.1 mg/mL (ultrasonic; warming; heat to 80°C)

Smiles

O=C1NN=C(CC2=CC=C(F)C(C(N3CCNCC3)=O)=C2)C4=C1C=CC=C4

Molecular Formula

C20H19FN4O2

Molecular Weight

366.40

Precautions

H302, H315, H319, H335

References & Citations

[1]Tao Huang, et al. Initial evaluation of Cu-64 labeled PARPi-DOTA PET imaging in mice with mesothelioma. Bioorg Med Chem Lett. 2017 Aug 1;27 (15) :3472-3476.|[2]Mengzhu Zheng, et al. Rational Design and Synthesis of Novel Dual PROTACs for Simultaneous Degradation of EGFR and PARP. J Med Chem. 2021 May 26.